pharmazentrum frankfurt and Center for Drug Research, Development and Safety (ZAFES), Institute of Clinical Pharmacology, Goethe-University Hospital, D-60590 Frankfurt am Main, Germany.
Trends Pharmacol Sci. 2012 Apr;33(4):193-9. doi: 10.1016/j.tips.2012.01.004. Epub 2012 Feb 21.
Advances in the understanding of the sense of smell have increased awareness of the role of olfaction in human life. Odors are perceived via specific G protein-coupled receptors (GPCRs) with cAMP as the second messenger. Drugs that interact with this signaling cascade, such as opioids, cannabinoids and sildenafil, are known to reduce olfactory function. Drugs that are active in the central nervous system (CNS) may also hinder the complex processing of olfactory information to distinguish, via pattern recognition, thousands of odors from the signals of only ∼400 distinct olfactory receptors. Many other interactions with drug targets expressed at the olfactory bulb are also likely to occur. However, olfactory drug effects have rarely been explored in controlled studies. In the current activities of drug development and re-purposing, olfaction could become highly important because it can impact significantly upon the enjoyment of food. With an established molecular basis and using available tools, the assessment of olfaction in drug development and approval is advised.
对嗅觉的认识的进步提高了人们对嗅觉在人类生活中作用的认识。气味是通过特定的 G 蛋白偶联受体(GPCR)感知的,cAMP 作为第二信使。已知与这种信号级联相互作用的药物,如阿片类药物、大麻素和西地那非,会降低嗅觉功能。作用于中枢神经系统(CNS)的药物也可能阻碍嗅觉信息的复杂处理,通过模式识别,从仅约 400 个不同嗅觉受体的信号中区分数千种气味。也可能发生许多其他与嗅球表达的药物靶点的相互作用。然而,嗅觉药物作用在对照研究中很少被探索。在当前的药物开发和再利用活动中,嗅觉可能变得非常重要,因为它会显著影响到对食物的享受。有了既定的分子基础和可用的工具,建议在药物开发和批准中评估嗅觉。